These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2389 related items for PubMed ID: 17317816

  • 1. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 2. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb 15; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 3. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.
    Haematologica; 2005 Apr 15; 90(4):534-41. PubMed ID: 15820950
    [Abstract] [Full Text] [Related]

  • 4. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N.
    Rinsho Byori; 2004 Feb 15; 52(2):136-44. PubMed ID: 15027317
    [Abstract] [Full Text] [Related]

  • 5. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V.
    Cas Lek Cesk; 2006 Feb 15; 145(5):377-82. PubMed ID: 16755775
    [Abstract] [Full Text] [Related]

  • 6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 15; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 7. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    Nat Rev Drug Discov; 2007 Oct 15; 6(10):834-48. PubMed ID: 17853901
    [Abstract] [Full Text] [Related]

  • 8. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R, Kimura S.
    Expert Rev Anticancer Ther; 2008 Sep 15; 8(9):1387-98. PubMed ID: 18759691
    [Abstract] [Full Text] [Related]

  • 9. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
    Nimmanapalli R, Bhalla K.
    Oncogene; 2002 Dec 09; 21(56):8584-90. PubMed ID: 12476305
    [Abstract] [Full Text] [Related]

  • 10. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Chen ZS.
    Leuk Res; 2010 Oct 09; 34(10):1255-68. PubMed ID: 20537386
    [Abstract] [Full Text] [Related]

  • 11. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 09; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 12. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A, Erben P, Ernst T, Mueller MC.
    Semin Hematol; 2007 Jan 09; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [Abstract] [Full Text] [Related]

  • 13. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
    Cang S, Liu D.
    J Hematol Oncol; 2008 Oct 01; 1():15. PubMed ID: 18828913
    [Abstract] [Full Text] [Related]

  • 14. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J.
    Semin Oncol; 2008 Feb 01; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [Abstract] [Full Text] [Related]

  • 15. Roots of imatinib resistance: a question of self-renewal?
    Burchert A.
    Drug Resist Updat; 2007 Feb 01; 10(4-5):152-61. PubMed ID: 17683977
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 01; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 18. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM.
    Cancer; 2007 Jun 01; 109(11):2171-81. PubMed ID: 17431887
    [Abstract] [Full Text] [Related]

  • 19. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E, Cortes J, Kantarjian H.
    Curr Opin Oncol; 2006 Nov 01; 18(6):578-83. PubMed ID: 16988578
    [Abstract] [Full Text] [Related]

  • 20. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW, Druker BJ.
    J Clin Invest; 2007 Aug 01; 117(8):2067-74. PubMed ID: 17671641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 120.